Patents Represented by Attorney, Agent or Law Firm Giulio A. DeConti, Jr.
-
Patent number: 6242667Abstract: Transgenic animals carrying a transgene comprising a nucleic acid molecule encoding protein useful for regulating the expression of genes in eukaryotic cells and organisms in a highly controlled manner are disclosed. In the regulatory system of the invention, transcription of a tet operator-linked nucleotide sequence is stimulated by a transcriptional activator fusion protein composed of two polypeptides, a first polypeptide which binds to tet operator sequences in the presence of tetracycline operatively linked to a second polypeptide activates transcription in eukaryotic cells. In a preferred embodiment, the transgene encoding the transcriptional activator fusion protein is integrated at a predetermined location within the chromosome of the transgenic animal.Type: GrantFiled: September 28, 1998Date of Patent: June 5, 2001Assignees: BASF Aktiengesellschaft, Knoll AktiengesekkscgaftInventors: Hermann Bujard, Manfred Gossen
-
Patent number: 6242201Abstract: Substances are disclosed which have the property of binding to PCNA, the substances comprising (i) a fragment of the p21WAF1 protein including residues 141 to 160 of the p21WAF1 amino acid sequence, or an active portion or derivative thereof; or (ii) functional mimetics of these protein fragments. In particular, the PCNA binding activity is shown to lie within the sequence motif OTSMTDFY, with the residues shown in bold being critical for PCNA binding, with those underlined being important. These substances are useful in the treatments of disorders in which PCNA is implicated, e.g. hyperproliferative disorders such as cancer and psoriasis, the substances binding to PCNA to inactivate it or functionally deplete its level. Also disclosed is the use of a yeast two hybrid screening technique for screening candidate peptides for binding to PCNA.Type: GrantFiled: August 22, 1997Date of Patent: June 5, 2001Assignee: Cyclacel LimitedInventors: David Philip Lane, Lynne Suzanne Cox, Emma Warbrick, David Moore Glover
-
Patent number: 6228370Abstract: Pharmaceutical compositions comprising known verotoxins, particularly, verotoxin 1, have been found to be useful in the treatment of mammalian neoplasia, particularly, ovarian cancer and skin cancer. Surprisingly, although verotoxin 1 has previously been shown to have anti-neoplastic activity in vitro, non-lethal doses of verotoxin 1 have been shown to be therapeutically anti-neoplastic in vivo.Type: GrantFiled: July 29, 1997Date of Patent: May 8, 2001Inventors: Clifford A. Lingwood, Hannah Farkas-Himsley, Richard Hill
-
Patent number: 6221873Abstract: The present invention is based on the method of treating a patient suffering from leukemia comprising administering a therapeutically effective amount of the compound 2-([(3-hydroxypropyl)amino]-6-benzylamino)-9-isopropylpurine or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 4, 1998Date of Patent: April 24, 2001Assignee: Institute of Experimental Botany of the Academy of Sciences of the Czech RepublicInventors: Libor Havlicek, Miroslav Strnad, Marian Hajduch
-
Patent number: 6217844Abstract: Improved methods for detecting lesions in dense breast tissue are disclosed. The methods of the invention generally feature administration to a subject of an LHRH antagonist in an amount and for a period of time sufficient to reduce the density of breast tissue prior to generating an image of the breast tissue, for example by mammography, to detect a lesion in the breast tissue. Packaged formulations for reducing breast density in a subject prior to generating an image of the subject's breast tissue, comprising an LHRH antagonist packaged with instructions for using the LHRH antagonist to reduce breast density in a subject prior to imaging the breast tissue, are also disclosed.Type: GrantFiled: April 27, 1998Date of Patent: April 17, 2001Assignee: Praecis Pharmaceuticals, Inc.Inventor: Marc B. Garnick
-
Patent number: 6214795Abstract: This invention provides peptide compounds that bind to either a fibroblast growth factor (FGF) or a fibroblast growth factor receptor (FGFR) and, accordingly, are useful for modulating FGFR activity. Preferably, the FGFR is FGFR2-IIIC. Preferably, the FGF is basic FGF. Preferably the peptide compound comprises an amino acid sequence: (Y/F)-(L/F/I)-(R/D/E/S/Y/G)-(Q/L/Y)-Y-(M/L/K/R)-(L/M/D/E/N/S)-(R/L/S/T)-(L/F/M/V) (SEQ ID NO: 1). The invention further comprises pharmaceutical compositions comprising the peptide compounds of the invention and a pharmaceutically acceptable carrier. The invention still further provides methods of modulating FGFR activity using the peptide compounds of the invention.Type: GrantFiled: November 12, 1996Date of Patent: April 10, 2001Assignee: Praecis Pharmaceuticals, Inc.Inventors: Howard Benjamin, Ling Chai, Mark A. Findeis, William Goodwin, Arvind Hundal, David I. Israel, Michael Kelley, Martin P. Keough, Kuanghui Lu, Farah Natoli, Alicia Peticolas, Ethan R. Signer, Malcolm L. Gefter
-
Patent number: 6211153Abstract: Methods for treating prostate cancer are disclosed. The methods of the invention generally feature administration to a subject of an LHRH-R antagonist, in combination with a second therapy. In one embodiment, this second therapy is performance of a procedure that removes or destroys prostatic tumor tissue, such as a radical prostatectomy, cryosurgery or X-ray therapy (external or interstitial). In another embodiment, the second therapy is treatment with an LHRH-R agonist, either simultaneous with or subsequent to LHRH-R antagonist therapy. The methods of the invention can further involve administering an antiandrogen and/or an inhibitor of sex steroid biosynthesis to the subject in combination with the LHRH-R antagonist.Type: GrantFiled: November 11, 1999Date of Patent: April 3, 2001Assignee: Praecis Pharmaceuticals, Inc.Inventors: Marc B. Garnick, Christopher J. Molineaux, Malcolm L. Gefter
-
Patent number: 6203977Abstract: This disclosure relates to a method of specifically decorating selected mammalian chromosomes and of detecting, identifying and and/or quantitating selected individual chromosomes, by means of chromosomal in situ suppression (CISS) hybridization. The method is useful in analyzing cells for the occurrence of chromosomes, chromosome fragments or chromosome aberrations.Type: GrantFiled: September 26, 1994Date of Patent: March 20, 2001Assignee: Yale UniversityInventors: David C. Ward, Peter Lichter, Thomas Cremer, Laura Manuelidis, Thomas Ried, Antonio Baldini
-
Patent number: 6197278Abstract: A method of imaging apoptosis in vivo, using radiolabeled annexin, is described.Type: GrantFiled: April 29, 1998Date of Patent: March 6, 2001Assignees: The Board of Trustees of the Leland Stanford Junior University, University of WashingtonInventors: Francis G. Blankenberg, H. William Strauss, Jonathan F. Tait, Peter D. Katsikis
-
Patent number: 6187550Abstract: Embodiments of the present invention are directed to non-naturally occurring cells and methods for screening compositions and genes which interact with interleukin 1 beta and interleukin-1 beta converting enzyme (ICE) processing, methods and non-naturally occurring cells for making ICE, and agonists and inhibitors of ICE.Type: GrantFiled: November 13, 1996Date of Patent: February 13, 2001Assignee: BASF AGInventors: Tariq Ghayur, Lorraine M. McGuinness
-
Patent number: 6180608Abstract: Sustained delivery formulations comprising a water-insoluble complex of a peptidic compound (e.g., a peptide, polypeptide, protein, peptidomimetic or the like) and a carrier macromolecule are disclosed. The formulations of the invention allow for loading of high concentrations of peptidic compound in a small volume and for delivery of a pharmaceutically active peptidic compound for prolonged periods, e.g., one month, after administration of the complex. The complexes of the invention can be milled or crushed to a fine powder. In powdered form, the complexes form stable aqueous suspensions and dispersions, suitable for injection. In a preferred embodiment, the peptidic compound of the complex is an LHRH analogue, preferably an LHRH antagonist, and the carrier macromolecule is an anionic polymer, preferably carboxymethylcellulose. Methods of making the complexes of the invention, and methods of using LHRH-analogue-containing complexes to treat conditions treatable with an LHRH analogue, are also disclosed.Type: GrantFiled: December 11, 1997Date of Patent: January 30, 2001Assignee: Praecis Pharmaceuticals, Inc.Inventors: Malcolm L. Gefter, Nicholas Barker, Gary Musso, Christopher J. Molineaux
-
Patent number: 6180609Abstract: Methods for treating prostate cancer are disclosed. The methods of the invention generally feature administration to a subject of an LHRH-R antagonist, in combination with a second therapy. In one embodiment, this second therapy is performance of a procedure that removes or destroys prostatic tumor tissue, such as a radical prostatectomy, cryosurgery or X-ray therapy (external or interstitial). In another embodiment, the second therapy is treatment with an LHRH-R agonist, either simultaneous with or subsequent to LHRH-R antagonist therapy. The methods of the invention can further involve administering an antiandrogen and/or an inhibitor of sex steroid biosynthesis to the subject in combination with the LHRH-R antagonist.Type: GrantFiled: November 11, 1999Date of Patent: January 30, 2001Assignee: Praecis Pharmaceuticals, Inc.Inventors: Marc B. Garnick, Christopher J. Molineaux, Malcolm L. Gefter
-
Patent number: 6168927Abstract: Disclosed is a transformed yeast cell containing a first heterologous DNA sequence which codes for a mammalian G protein coupled receptor and a second heterologous DNA sequence which codes for a mammalian G protein &agr; subunit (mammalian G&agr;). The first and second heterologous DNA sequences are capable of expression in the cell, but the cell is incapable of expressing an endogenous G protein &agr;-subunit (yeast G&agr;) The cells are useful for screening compounds which affect the rate of dissociation of G&agr; from G&bgr;&ggr; in a cell. Also disclosed is a novel DNA expression vector useful for making cells as described above. The vector contains a first segment comprising at least a fragment of the extreme amino-terminal coding sequence of a yeast G protein coupled receptor. A second segment is positioned downstream from the first segment (and in correct reading frame therewith), with the second segment comprising a DNA sequence encoding a heterologous G protein coupled receptor.Type: GrantFiled: April 8, 1998Date of Patent: January 2, 2001Assignee: Duke UniversityInventors: Klim King, Henrik G. Dohlman, Marc G. Caron, Robert J. Lefkowitz
-
Patent number: 6136954Abstract: Methods of regulating gene expression in subjects using tetracycline-responsive fusion proteins are disclosed. In one embodiment, the method involves introducing into a cell the subject a nucleic acid molecule encoding a fusion protein which inhibits transcription, the fusion protein comprising a first polypeptide which binds to a tet operator sequence, operatively linked to a heterologous second polypeptide which inhibits transcription in eukaryotic cells; and modulating the concentration of a tetracycline, or analogue thereof, in the subject. The first polypeptide can binds to a tet operator sequence in the absence, but not the presence, of tetracycline. Alternatively, the first polypeptide can binds to a tet operator sequence in the presence, but not the absence, of tetracycline.Type: GrantFiled: September 28, 1998Date of Patent: October 24, 2000Assignees: BASF Aktiengesellschaft, Knoll AktiengesellschaftInventors: Hermann Bujard, Manfred Gossen
-
Patent number: 6063621Abstract: A novel protein associated with multidrug resistance in living cells and capable of conferring multidrug resistance on a cell is disclosed. Nucleic acids encoding the novel multidrug resistance protein are also disclosed. Transformant cell lines which express the nucleic acid encoding the novel protein are also disclosed. Antibodies which bind the novel multidrug resistance protein are also disclosed. Diagnostic and treatment methods using the novel proteins, nucleic acids, antibodies and cell lines of the invention are also encompassed by the invention.Type: GrantFiled: March 20, 1995Date of Patent: May 16, 2000Assignee: Queen's University at KingstonInventors: Roger G. Deeley, Susan P. C. Cole
-
Patent number: 6024966Abstract: A Plasmodium falciparum gene encoding immunogenic SERA protein has been isolated by a) systematically screening a lambda gt11 recombinant DNA expression library with a murine monoclonal antibody directed against protein antigens of this pathogen, and b) systematically screening a lambda gt11 genomic cDNA and oligonucleotide probes directed against this pathogen. A 111 kDa protein has been shown to have immunogenic activity against parasite inhibitory antibodies. The gene encoding this protein, including the signal sequence and regulatory sequence in the adjacent 5' flanking sequence has been isolated and sequenced.Isolation and characterization of genes encoding major protein antigens of P. falciparum make it possible to develop reagents useful in the diagnosis, prevention and treatment of malaria. In addition, the signal sequences or regulatory sequences of this gene can be used to stimulate the production of other useful genetic products.Type: GrantFiled: November 7, 1994Date of Patent: February 15, 2000Assignee: Trustees of Dartmouth CollegeInventors: Joseph W. Inselburg, David J. Bzik
-
Patent number: 6025473Abstract: A novel protein associated with multidrug resistance in living cells and capable of conferring multidrug resistance on a cell is disclosed. Nucleic acids encoding the novel multidrug resistance protein are also disclosed. Transformant cell lines which express the nucleic acid encoding the novel protein are also disclosed. Antibodies which bind the novel multidrug resistance protein are also disclosed. Diagnostic and treatment methods using the novel proteins, nucleic acids, antibodies and cell lines of the invention are also encompassed by the invention.Type: GrantFiled: June 5, 1995Date of Patent: February 15, 2000Assignee: Queen's University at KingstonInventors: Roger G. Deeley, Susan P. C. Cole
-
Patent number: 6001563Abstract: A novel protein associated with multidrug resistance in living cells and capable of conferring multidrug resistance on a cell is disclosed. Nucleic acids encoding the novel multidrug resistance protein are also disclosed. Transformant cell lines which express the nucleic acid encoding the novel protein are also disclosed. Antibodies which bind the novel multidrug resistance protein are also disclosed. Diagnostic and treatment methods using the novel proteins, nucleic acids, antibodies and cell lines of the invention are also encompassed by the invention.Type: GrantFiled: June 5, 1995Date of Patent: December 14, 1999Assignee: Queen's University at KingstonInventors: Roger G. Deeley, Susan P.C. Cole
-
Patent number: 5935829Abstract: The present invention pertains to a line of human blood cells which have high levels of oxidative activity (such as oxygenase, oxidase, peroxidase, and hydroxylase activity). Such cells grow in suspension culture, and are useful to determine the mutagenicity of xenobiotic substances that are metabolized into toxic or mutagenic substances. The invention also includes mutation assays using these cells, and other cells with similar characteristics.Type: GrantFiled: January 6, 1992Date of Patent: August 10, 1999Assignee: Massachusetts Institute of TechnologyInventors: Charles L. Crespi, William G. Thilly
-
Patent number: 5891724Abstract: A novel protein associated with multidrug resistance in living cells and capable of conferring multidrug resistance on a cell is disclosed. Nucleic acids encoding the novel multidrug resistance protein are also disclosed. Transformant cell lines which express the nucleic acid encoding the novel protein are also disclosed. Antibodies which bind the novel multidrug resistance protein are also disclosed. Diagnostic and treatment methods using the novel proteins, nucleic acids, antibodies and cell lines of the invention are also encompassed by the invention.Type: GrantFiled: June 5, 1995Date of Patent: April 6, 1999Assignee: Queen's University at KingstonInventors: Roger G. Deeley, Susan P. C. Cole